Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Completed
ICON Bioscience Inc
Phase 3
2015-11-06
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40
years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion
criteria will be randomized to 1 of 2 treatment groups
- A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone,
equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or;
- Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times
daily (QID) for 3 weeks Safety will be assessed by adverse events (AEs), slit lamp
biomicroscopy, fundus examination, intraocular pressure (IOP), visual acuity, and
specular microscopy endothelial cell count.
Effect of Intraoperative Dexamethasone on Post-op Dry Eye
Completed
SR Cornea Consultants
Phase 4
2019-08-10
To compare the signs and symptoms of dry eye after cataract surgery between subjects
randomized to receive intraoperative dexamethasone in addition to the use of a standard
topical post-op treatment regimen.
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
Completed
MDbackline, LLC
Phase 4
2019-12-16
This is a post-approval, open-label, randomized, self-controlled prospective clinical study
to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain
and inflammation associated with cataract surgery.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
